80 related articles for article (PubMed ID: 2751259)
1. Cellular pharmacology of doxorubicinol alone and combined with verapamil in pancreatic cancer cell lines.
Chang BK; Brenner DE; Gutman R
Anticancer Res; 1989; 9(2):341-5. PubMed ID: 2751259
[TBL] [Abstract][Full Text] [Related]
2. Dissociation of the verapamil-induced enhancement of doxorubicin's cytotoxicity from changes in cellular accumulation or retention of doxorubicin in pancreatic cancer cell lines.
Chang BK; Brenner DE; Gutman R
Anticancer Res; 1989; 9(2):347-51. PubMed ID: 2751260
[TBL] [Abstract][Full Text] [Related]
3. Verapamil-mediated sensitization of doxorubicin-selected pleiotropic resistance in human sarcoma cells: selectivity for drugs which produce DNA scission.
Harker WG; Bauer D; Etiz BB; Newman RA; Sikic BI
Cancer Res; 1986 May; 46(5):2369-73. PubMed ID: 3754487
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
Slovak ML; Hoeltge GA; Dalton WS; Trent JM
Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
[TBL] [Abstract][Full Text] [Related]
5. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.
Tsuruo T; Iida H; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Feb; 43(2):808-13. PubMed ID: 6848194
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
8. Separation of doxorubicin and doxorubicinol by cyclodextrin-modified micellar electrokinetic capillary chromatography.
Eder AR; Chen JS; Arriaga EA
Electrophoresis; 2006 Aug; 27(16):3263-70. PubMed ID: 16915573
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin cellular pharmacokinetics plays no role in chemosensitizing effect of verapamil on Swiss-3T3 cells.
Wang N; Tang ZM; Zhang YP; Ding QM
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):402-6. PubMed ID: 9863159
[TBL] [Abstract][Full Text] [Related]
10. Modulation of doxorubicin-induced DNA lesions by verapamil, DMDP and dipyridamole in resistant P388 cell lines.
Yin MB; Bankusli I; Frank C; Rustum YM
Anticancer Res; 1990; 10(2A):327-32. PubMed ID: 2346306
[TBL] [Abstract][Full Text] [Related]
11. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
Sebille S; Morjani H; Poullain MG; Manfait M
Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
[TBL] [Abstract][Full Text] [Related]
12. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
13. Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance.
Kang Y; Perry RR
Cancer Res; 1993 Jul; 53(13):3040-5. PubMed ID: 8100483
[TBL] [Abstract][Full Text] [Related]
14. A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin.
Bains OS; Szeitz A; Lubieniecka JM; Cragg GE; Grigliatti TA; Riggs KW; Reid RE
J Pharmacol Exp Ther; 2013 Nov; 347(2):375-87. PubMed ID: 23995598
[TBL] [Abstract][Full Text] [Related]
15. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
16. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents.
Berger B; Marquardt H; Westendorf J
Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856
[TBL] [Abstract][Full Text] [Related]
18. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of the in vivo resistance to adriamycin and modulation by calcium channel blockers in mice.
Yin MB; Bankusli I; Rustum YM
Cancer Res; 1989 Sep; 49(17):4729-33. PubMed ID: 2758408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
